Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors
- PMID: 9191522
Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors
Abstract
Background: Once melanoma has metastasized to distant sites, the prognosis is usually poor, showing an overall median survival of 6-8 months. Long term survival is extremely rare, and there is still controversy concerning the prognostic significance of therapeutic modalities. The aim of the current study was to identify important prognostic factors associated with Stage IV melanoma.
Methods: The current study was based on data for 3258 melanoma patients, for whom clinical, pathologic, and long term follow-up information was recorded during the period 1976-1996 at the Eberhard-Karls-University in Tuebingen. Germany. The attainment of 2 years' or longer survival time by patients with disseminated melanoma was addressed, and a multivariate analysis of related prognostic factors was performed by logistic regression.
Results: Four hundred forty-two patients (13.6%) developed distant metastasis. The median survival time was 7 months, and the 2-year, 5-year, and 10-year survival rates were 11.9%, 6.7%, and 4.7%, respectively. Forty-five patients had prolonged survival of 2 years or longer. Significantly more females belonged to the group of long term survivors (P = 0.0186). Of the modalities of therapy given, only surgery was associated with prolonged survival (P < 0.0001). Primary metastasis to the skin (P = 0.006), the brain (P = 0.015), more than a single metastatic site (P = 0.002), and Karnofsky performance status of less than 80 (P = 0.0035) were significantly related to short term survival. In addition, subsequent development of two or more new metastatic sites was also associated with short term survival (P = 0.0025).
Conclusions: In the current analysis, prolonged survival of 2 years or longer for patients with disseminated melanoma was shown to depend on gender, site of primary metastasis, number of metastatic sites, and Karnofsky performance status. Of the modalities of therapy given, only surgery significantly influenced survival. However, in a small percentage of patients, long term complete remission was achieved with chemotherapy alone or in combination with surgery, suggesting that such regimens might be curative in selected cases.
Similar articles
-
Prognostic factors in 1,521 melanoma patients with distant metastases.J Am Coll Surg. 1995 Sep;181(3):193-201. J Am Coll Surg. 1995. PMID: 7670677
-
Treatment of maxillary sinus carcinoma: a comparison of the 1997 and 1977 American Joint Committee on cancer staging systems.Cancer. 1999 Nov 1;86(9):1700-11. Cancer. 1999. PMID: 10547542
-
Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.Oncologist. 2009 Oct;14(10):995-1002. doi: 10.1634/theoncologist.2009-0083. Epub 2009 Sep 23. Oncologist. 2009. PMID: 19776094
-
[Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical excision].Ann Dermatol Venereol. 1991;118(4):287-95. Ann Dermatol Venereol. 1991. PMID: 2069340 Review. French.
-
[Current aspects in the treatment of malignant melanoma].Schweiz Med Wochenschr. 1994 Sep 10;124(36):1592-603. Schweiz Med Wochenschr. 1994. PMID: 7939527 Review. German.
Cited by
-
Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.Neuro Oncol. 2008 Apr;10(2):199-207. doi: 10.1215/15228517-2007-058. Epub 2008 Feb 20. Neuro Oncol. 2008. PMID: 18287337 Free PMC article.
-
Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.J Natl Cancer Inst. 2020 Sep 1;112(9):875-885. doi: 10.1093/jnci/djaa012. J Natl Cancer Inst. 2020. PMID: 32061122 Free PMC article. Review.
-
Effects of the IL6 -174G>C promoter polymorphism and IL-6 serum levels on the progression of cutaneous malignant melanoma.Oncol Lett. 2020 Aug;20(2):1781-1791. doi: 10.3892/ol.2020.11740. Epub 2020 Jun 16. Oncol Lett. 2020. PMID: 32724421 Free PMC article.
-
The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma: serum IL-6 level is a valuable prognostic factor at least as serum LDH in advanced melanoma.Med Oncol. 2005;22(3):241-6. doi: 10.1385/MO:22:3:241. Med Oncol. 2005. PMID: 16110135 Clinical Trial.
-
Long-term survival in patients with metastatic melanoma treated with DTIC or temozolomide.Oncologist. 2010;15(7):765-71. doi: 10.1634/theoncologist.2009-0237. Epub 2010 Jun 10. Oncologist. 2010. PMID: 20538743 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical